Zobrazeno 1 - 10
of 1 034
pro vyhledávání: '"Arban R"'
Autor:
Fer M; Domain Therapeutics, 67400 Illkirch, France., Amalric C; Domain Therapeutics, 67400 Illkirch, France., Arban R; Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany., Baron L; Domain Therapeutics, 67400 Illkirch, France., Ben Hamida S; Douglas Research Center, Department of Psychiatry, McGill University, Montréal, Quebec H4H 1R3, Canada.; INSERM UMR 1247- Research Group on Alcohol & Pharmacodependences (GRAP), Université de Picardie Jules Verne, 80000 Amiens, France., Breh-Schlanser P; Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany., Cui Y; Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany., Darcq E; Douglas Research Center, Department of Psychiatry, McGill University, Montréal, Quebec H4H 1R3, Canada.; INSERM UMR-S1329, Strasbourg Translational Neuroscience & Psychiatry, University of Strasbourg, Strasbourg 67084, France., Eickmeier C; Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany., Faye V; Domain Therapeutics, 67400 Illkirch, France., Franchet C; Domain Therapeutics, 67400 Illkirch, France., Frauli M; Domain Therapeutics, 67400 Illkirch, France., Halter C; Domain Therapeutics, 67400 Illkirch, France., Heyer M; Domain Therapeutics, 67400 Illkirch, France., Hoenke C; Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany., Hoerer S; Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany., Hucke OT; Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany., Joseph C; Domain Therapeutics, 67400 Illkirch, France., Kieffer BL; Douglas Research Center, Department of Psychiatry, McGill University, Montréal, Quebec H4H 1R3, Canada.; INSERM UMR-S1329, Strasbourg Translational Neuroscience & Psychiatry, University of Strasbourg, Strasbourg 67084, France., Lebrun L; Domain Therapeutics, 67400 Illkirch, France., Lotz N; Domain Therapeutics, 67400 Illkirch, France., Mayer S; Domain Therapeutics, 67400 Illkirch, France., Omrani A; Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany., Recolet M; Domain Therapeutics, 67400 Illkirch, France., Schaeffer L; Domain Therapeutics, 67400 Illkirch, France., Schann S; Domain Therapeutics, 67400 Illkirch, France., Schlecker A; Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany., Steinberg E; Domain Therapeutics, 67400 Illkirch, France., Viloria M; Domain Therapeutics, 67400 Illkirch, France., Würstle K; Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany., Young K; Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany., Zinser A; Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany., Montel F; Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany., Klepp J; Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2024 Jul 11; Vol. 67 (13), pp. 11296-11325. Date of Electronic Publication: 2024 Jul 01.
Autor:
Hinchcliffe JK; School of Physiology, Pharmacology and Neuroscience, University of Bristol, Biomedical Sciences Building, Bristol BS8 1TD, UK., Stuart SA; School of Physiology, Pharmacology and Neuroscience, University of Bristol, Biomedical Sciences Building, Bristol BS8 1TD, UK., Wood CM; Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge CB3 2DY, UK., Bartlett J; School of Physiology, Pharmacology and Neuroscience, University of Bristol, Biomedical Sciences Building, Bristol BS8 1TD, UK., Kamenish K; School of Physiology, Pharmacology and Neuroscience, University of Bristol, Biomedical Sciences Building, Bristol BS8 1TD, UK., Arban R; CNS Diseases Research, Boehringer Ingelheim GmbH & Co. KG, Biberach an der Riss, Germany., Thomas CW; COMPASS Pathways plc, London W1F 0DQ, UK., Selimbeyoglu A; COMPASS Pathways plc, London W1F 0DQ, UK., Hurley S; COMPASS Pathways plc, London W1F 0DQ, UK., Hengerer B; CNS Diseases Research, Boehringer Ingelheim GmbH & Co. KG, Biberach an der Riss, Germany., Gilmour G; COMPASS Pathways plc, London W1F 0DQ, UK., Robinson ESJ; School of Physiology, Pharmacology and Neuroscience, University of Bristol, Biomedical Sciences Building, Bristol BS8 1TD, UK.
Publikováno v:
Science translational medicine [Sci Transl Med] 2024 Jan 10; Vol. 16 (729), pp. eadi2403. Date of Electronic Publication: 2024 Jan 10.
Publikováno v:
In Neuroscience Applied 2022 1 Supplement 2
Autor:
Hales CA; Faculty of Biomedical Sciences, School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK., Bartlett JM; Faculty of Biomedical Sciences, School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK., Arban R; CNS Diseases Research, Boehringer Ingelheim GmbH & Co. KG, Biberach an der Riss, Germany., Hengerer B; CNS Diseases Research, Boehringer Ingelheim GmbH & Co. KG, Biberach an der Riss, Germany., Robinson ES; Faculty of Biomedical Sciences, School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK.
Publikováno v:
The European journal of neuroscience [Eur J Neurosci] 2022 May; Vol. 55 (9-10), pp. 2955-2970. Date of Electronic Publication: 2021 Feb 21.
Major Depressive Disorder is a significant and costly cause of global disability. Until the discovery of the rapid acting antidepressant (RAAD) effects of ketamine, treatments were limited to drugs that have delayed clinical benefits. The mechanism o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=sharebioRxiv::5e6fc96e16262b667802236c6f067297
Autor:
Hales CA; University of Bristol, School of Physiology, Pharmacology & Neuroscience, Biomedical Sciences, University Walk, Bristol BS8 1TD, UK; Department of Psychology, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, 2215 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada., Stuart SA; University of Bristol, School of Physiology, Pharmacology & Neuroscience, Biomedical Sciences, University Walk, Bristol BS8 1TD, UK., Griffiths J; University of Bristol, School of Physiology, Pharmacology & Neuroscience, Biomedical Sciences, University Walk, Bristol BS8 1TD, UK., Bartlett J; University of Bristol, School of Physiology, Pharmacology & Neuroscience, Biomedical Sciences, University Walk, Bristol BS8 1TD, UK., Arban R; CNS Diseases Research, Boehringer Ingelheim Pharma Gmbh & Co. KG, Biberach an der Riss, Germany., Hengerer B; CNS Diseases Research, Boehringer Ingelheim Pharma Gmbh & Co. KG, Biberach an der Riss, Germany., Robinson ES; University of Bristol, School of Physiology, Pharmacology & Neuroscience, Biomedical Sciences, University Walk, Bristol BS8 1TD, UK. Electronic address: emma.s.j.robinson@bristol.ac.uk.
Publikováno v:
Psychoneuroendocrinology [Psychoneuroendocrinology] 2023 Jan; Vol. 147, pp. 105953. Date of Electronic Publication: 2022 Oct 19.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Babaev O; Central Nervous System Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany. Electronic address: olga.babaev@boehringer-ingelheim.com., Cruces-Solis H; Central Nervous System Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany., Arban R; Central Nervous System Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.
Publikováno v:
Neuropharmacology [Neuropharmacology] 2022 Jun 15; Vol. 211, pp. 109056. Date of Electronic Publication: 2022 Apr 06.
Autor:
Sbarbati, A *, Reggiani, A, Nicolato, E, Arban, R, Bernardi, P, Lunati, E, Asperio, R.M, Marzola, P, Osculati, F
Publikováno v:
In Magnetic Resonance Imaging 2002 20(6):479-486
Autor:
Scarborough J; Institute of Pharmacology and Toxicology, University of Zürich-Vetsuisse, Zürich, Switzerland., Mattei D; Institute of Pharmacology and Toxicology, University of Zürich-Vetsuisse, Zürich, Switzerland., Dorner-Ciossek C; Department of CNS Discovery Research, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany., Sand M; Department of Medicine, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA., Arban R; Department of CNS Discovery Research, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany., Rosenbrock H; Department of CNS Discovery Research, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany., Richetto J; Institute of Pharmacology and Toxicology, University of Zürich-Vetsuisse, Zürich, Switzerland.; Neuroscience Center Zürich, University of Zürich and ETH Zürich, Zürich, Switzerland., Meyer U; Institute of Pharmacology and Toxicology, University of Zürich-Vetsuisse, Zürich, Switzerland. urs.meyer@vetpharm.uzh.ch.; Neuroscience Center Zürich, University of Zürich and ETH Zürich, Zürich, Switzerland. urs.meyer@vetpharm.uzh.ch.
Publikováno v:
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology [Neuropsychopharmacology] 2021 Jul; Vol. 46 (8), pp. 1526-1534. Date of Electronic Publication: 2021 May 03.